José C. Román-Liñán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
José C. Román-Liñán has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bernardino Clavo
Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain
1 shared publication - Carmen G. Pérez-Santana
Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain
1 shared publication - David Morales-Alamo
Department of Physical Education and Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
1 shared publication - Francisco Rodríguez-Esparragón
Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain
1 shared publication - Gregorio Martínez-Sánchez
Instituto de Investigación Sanitaria de Canarias (IISC), 35019 Las Palmas de Gran Canaria, Spain
1 shared publication - Juan Antonio Díaz-Garrido
Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (11) , 1480
Chemotherapy-Induced Cognitive Impairment (CICI): Pathophysiological Mechanisms and the Rationale for Investigating Ozone Therapy
Chemotherapy-induced cognitive impairment (CICI) is an increasingly recognized complication of cancer treatment, particularly among breast cancer survivors, characterized by persistent difficulties in memory, attention, executive function, and processing speed. This review summarizes current evidence on the clinical phenotype and biological mechanisms of CICI and examines the rationale for investigating medical ozone as a redox-modulating intervention. A translational narrative review was conducted using literature published between 2000 and September 2026, retrieved from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, complemented by manual reference-list screening. Clinical, preclinical, mechanistic, and evidence-synthesis studies were examined to critically assess the pathophysiology of CICI and the biological rationale for investigating ozone-induced redox modulation. Current evidence points to a multifactorial pathophysiology of CICI and provides a rationale for testing whether controlled redox modulation can influence some of the pathways involved, including activation of endogenous antioxidant and adaptive pathways. Preliminary evidence from chemotherapy-induced peripheral neuropathy and selected neurological or cognitive conditions provides indirect translational support, but does not establish efficacy in CICI. Medical ozone should therefore be considered investigational in this context. The hypothesis should be tested in randomized, sham-controlled trials using validated cognitive outcomes, mechanistic biomarkers, and appropriate oncological safety monitoring to determine whether ozone-induced redox adaptation can produce clinically meaningful cognitive benefit.
- 16 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (11) , 1480
Open AccessChemotherapy-Induced Cognitive Impairment (CICI): Pathophysiological Mechanisms and the Rationale for Investigating Ozone Therapy
Chemotherapy-induced cognitive impairment (CICI) is an increasingly recognized complication of cancer treatment, particularly among breast cancer survivors, characterized by persistent difficulties in memory, attention, executive function, and processing speed. This review summarizes current evidence on the clinical phenotype and biological mechanisms of CICI and examines the rationale for investigating medical ozone as a redox-modulating intervention. A translational narrative review was conducted using literature published between 2000 and September 2026, retrieved from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, complemented by manual reference-list screening. Clinical, preclinical, mechanistic, and evidence-synthesis studies were examined to critically assess the pathophysiology of CICI and the biological rationale for investigating ozone-induced redox modulation. Current evidence points to a multifactorial pathophysiology of CICI and provides a rationale for testing whether controlled redox modulation can influence some of the pathways involved, including activation of endogenous antioxidant and adaptive pathways. Preliminary evidence from chemotherapy-induced peripheral neuropathy and selected neurological or cognitive conditions provides indirect translational support, but does not establish efficacy in CICI. Medical ozone should therefore be considered investigational in this context. The hypothesis should be tested in randomized, sham-controlled trials using validated cognitive outcomes, mechanistic biomarkers, and appropriate oncological safety monitoring to determine whether ozone-induced redox adaptation can produce clinically meaningful cognitive benefit.